McKesson Corporation
NYSE•MCK
CEO: Mr. Brian S. Tyler Ph.D.
Sector: Healthcare
Industry: Medical - Distribution
Listing Date: 1994-11-10
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners, and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Contact Information
Market Cap
$116.42B
P/E (TTM)
26.8
32.2
Dividend Yield
0.3%
52W High
$999.00
52W Low
$637.00
52W Range
Rank12Top 1.7%
6.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2026 Data
Revenue
$106.16B+0.00%
4-Quarter Trend
EPS
$9.63+0.00%
4-Quarter Trend
FCF
$1.12B+0.00%
4-Quarter Trend
2026 Q3 Earnings Highlights
Key Highlights
Nine Month Revenue Growth Nine months revenues hit $307.1B USD, showing strong 15% growth compared to prior year period results.
Profitability Surge Net income attributable to McKesson grew 51% to $3.08B USD for the nine months ended December 31, 2025.
Acquisition Integration Total acquisition consideration reached $3.38B USD, integrating PRISM Vision and Core Ventures into specialty care.
Diluted EPS Jump Diluted EPS grew 57% to $24.73 USD for the nine months ended December 31, 2025 compared to prior year.
Risk Factors
Opioid Litigation Exposure Estimated total opioid litigation liability stands at $5.7B USD as of December 31, 2025, subject to future settlements.
Rite Aid Bankruptcy Impact Immaterial $29M net charge recorded due to customer Rite Aid bankruptcy provisions during the nine months period.
Regulatory Uncertainty Risk Industry highly regulated; rapid changes in healthcare policy pose ongoing operational risks affecting future outcomes.
Goodwill Impairment Risk Future impairment possible due to government actions and material changes in key market assumptions limiting cash flow estimates.
Outlook
Medical-Surgical Separation Plan Intention announced to separate Medical-Surgical Solutions segment into an independent company effective in fiscal 2026.
Enterprise Restructuring Costs Enterprise-wide modernization initiatives anticipate total charges of $650M to $700M, expected to be substantially complete in fiscal 2028.
Dividend Increase Policy Quarterly dividend raised to $0.82 from $0.71 per share, reflecting commitment to capital return strategy.
Norway Divestiture Complete Agreement signed to sell Norway operations; sale completed January 30, 2026, impacting 'Other' segment reporting.
Peer Comparison
Revenue (TTM)
$402.07B
$397.96B
$325.78B
Gross Margin (Latest Quarter)
85.6%
70.3%
69.7%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| SYK | $133.77B | 41.2 | 15.0% | 31.1% |
| BMY | $121.60B | 17.3 | 39.3% | 52.4% |
| VRTX | $118.39B | 29.9 | 22.7% | 14.9% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.3%
Steady Growth
4Q Net Income CAGR
-2.0%
Stable Profitability
Cash Flow Stability
75%
Volatile Cash Flow
Deep Research
Next earnings:May 6, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data